FDA approval positions Titan Prime as Coloplast’s updated IPP option for men with severe erectile dysfunction seeking long-term prosthetic restoration of erectile function. Improved flaccid ...
The 2026 AUA Annual Meeting will feature significant bladder cancer data, a plenary lecture on screening and overdetection, and programming that integrates advanced practice providers across sessions, ...
Prespecified interim analysis showed neither pembrolizumab/lenvatinib/belzutifan nor MK-1308A (pembrolizumab/quavonlimab) plus lenvatinib improved dual primary ...
FDA 510(k) clearance enables use of external neuromuscular stimulation to strengthen pelvic floor musculature and improve bladder control in men with post-prostatectomy incontinence. Daily home ...
Alex Tatem, MD, explains that hyaluronic acid penile injections add temporary, measurable girth by safely distributing a reversible filler within soft tissue, though outcomes depend heavily on ...
The first-ever guideline on genitourinary syndrome of menopause (GSM) was released, providing evidence-based guidance for managing this condition in urologic care. The FDA removed the black box ...
Hormonal changes influence fluid balance and bloating, increasing pressure within the pelvis. In this video, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, founder of the Fosnight Center ...
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS. 2025 will likely be remembered as a pivotal chapter in ...
In this video, sisters Amy Pearlman, MD, and Michelle Pearlman, MD, provide an overview of their shared practice, Prime Institute, a concierge-style private practice built around personalized, patient ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Nadofaragene firadenovec offers a non-chemotherapy option for high-risk BCG-unresponsive NMIBC, transforming bladder cells into interferon-producing factories. The phase 3 trial in Japan showed a 75% ...
TAR-200 monotherapy achieved an 82.4% complete response rate in BCG-unresponsive high-risk NMIBC, with a median duration of response of 25.8 months. The 12- and 24-month radical cystectomy-free rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results